Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year Period End

31 December 2020

Interim Dividend Payment

23 October 2020

Interim Results Announcement

16 September 2020

Half Year Period End

30 June 2020

Final Dividend Payment

19 June 2020

Annual General Meeting

10 June 2020 (Closed Meeting)

Preliminary Results Announcement

11 March 2020
View Full Calendar

Financial Reports

2020 Interim Report

September 2020

Notice of AGM

May 2020

2019 Interim Report

September 2019

2018 Interim Report

September 2018

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports

News

Acquisition of Raleigh Coatings

Advanced Medical Solutions Group plc today announces that it has acquired Raleigh Adhesive Coatings Limited (“Raleigh”), an independent woundcare and bio-diagnostics... Read More

Acquisition of Biomatlante

Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More

View More News

Latest Highlights

The Group has faced an unprecedented first half of 2020 as a result of the severe impact on our core markets arising from the COVID-19 pandemic. As a business, we have responded well to the challenge, prioritising our employees’ safety and continuing critical supply to customers. Whilst the short-term impact has been stark, we are proud that the Group remains profitable and cash generative during this time whilst maintaining the dividend and a robust balance sheet.

Trading was in line with the trading update of 9 July 2020, with the majority of the business impacted by government-led restrictions to control COVID-19 and a slowdown in demand across all regions and product categories. All manufacturing sites have remained in operation throughout the COVID-19 pandemic, servicing customers and order demand, and having implemented strict controls to ensure employee safety at all times.

First half revenue was £39.3 million, down by 19% on a reported and constant currency basis. Despite the significant challenges, the Group reported an adjusted operating profit of £5.5 million and a 6% increase in net cash to £67.9 million. The US LiquiBand® recovery plan remains on track with sales initiatives recovering 2% share of end market volumes. LiquiBand® Rapid launched with a key partner as planned and regained product listings on the two previously lost Group Purchasing Organisation (GPO) contracts.

Investment has been maintained in R&D to progress key projects and we are well positioned for growth as our markets continue to recover. Whilst we expect COVID-19 to continue to impact sales and profitability in the short-term, the Board remains positive about our medium to long-term prospects.

Product approvals for new geographies have continued with our first approvals in India for both LiquiBand® and LiquiBandFix8®. Patents have been granted for LiquiBand® Exceed in the UK and US, providing protection and tax benefits until 2034.